Compare PM & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PM | MRK |
|---|---|---|
| Founded | 1987 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.8B | 260.2B |
| IPO Year | N/A | N/A |
| Metric | PM | MRK |
|---|---|---|
| Price | $159.15 | $101.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 15 |
| Target Price | ★ $190.44 | $111.93 |
| AVG Volume (30 Days) | 5.8M | ★ 15.2M |
| Earning Date | 02-05-2026 | 02-03-2026 |
| Dividend Yield | ★ 3.74% | 3.38% |
| EPS Growth | N/A | ★ 58.08 |
| EPS | 5.52 | ★ 7.56 |
| Revenue | $39,992,000,000.00 | ★ $64,235,000,000.00 |
| Revenue This Year | $10.82 | $1.97 |
| Revenue Next Year | $7.66 | $4.96 |
| P/E Ratio | $28.49 | ★ $13.33 |
| Revenue Growth | ★ 7.45 | 1.68 |
| 52 Week Low | $116.12 | $73.31 |
| 52 Week High | $186.69 | $105.84 |
| Indicator | PM | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 58.23 | 60.28 |
| Support Level | $156.49 | $96.79 |
| Resistance Level | $159.87 | $100.94 |
| Average True Range (ATR) | 3.19 | 2.32 |
| MACD | 0.86 | -0.45 |
| Stochastic Oscillator | 87.50 | 71.71 |
Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heat sticks, vapes, and oral nicotine offerings, primarily outside of the US. With the 2023 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI is not only dominant in smokable products but also has the Iqos and Zyn brands, which respectively dominate heated tobacco and nicotine pouches in most markets.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).